We would love to hear your thoughts about our site and services, please take our survey here.
The milestone lines have vanished , that was how " the entered clinical trial " was identified in a previous post .
Also in the last RNS per previously noted by someone there is conflicting statements re Company v Tim about the status of 1801 CTA - entering shortly or already approved
Check out the pipeline diagram on Sareum website .
Appart from the update re the SAR 737 status regarding the return .
Anyone else notice something strange ?
A phone glitch or deliberate
That's a fund that has dumped '
- They have a bandwith - that bandwidth was breached - They do what they have to do.
It is , or should not be of any concern to PI's
Lets say GSK evaluated SRA737 ( they must have ) and whether that was done directly by them or what they were told by Sierra is anyones guess .
The RNS states Sareum were informed by Sierra .
At the last Q&A the chairmam made the point that Sareum had no direct discussions re SRA 737 and discussions were directly between Sierra ( GSK ) and CPF . Why did that arrangement change ?
By all accounts the compound as a part therapy works very well as per the Slide that Tim produced at a previous investor presentation .
Could as a part of a takeover be it simpler to hand our % back then the paperwork and formalities become easier to deal with.
I know in the RNS Tim states it means we have more control in future development but that may already have been worked out and it is just something he is compelled to say .
Or maybe someone else is waiting in the wings .
Who knows ! - All smoke and mirrors
Why hand it back ? - maybe they had no choice - other than paying thro the nose for it to a rival .
Perhaps they do not fancy paying royalties to a bigger bidder - ???
Master McGrath is back - and after hours too , that can only be a good thing
We are moving ever closer to the split the nut scenario - How much that is worth is anyones guess - I think 2.3 to 3.2
Newsnight - many years ago and Paxman is interviewing some Tory " fixer " that oversees experimental human trials at Aldermaston .
Paxman looking bewildered after the initial discussion says : " So what you are saying is you actually administer geneneticly modified bubonic plague in humans ? " Without missing a breath he reply's " Yes - they get well paid "
Just a guess but why leave any announcement till the very last minute - unless ofcourse it is a part of a much larger piece of news.
No Bone ( milk ) Today - Hermans Hermits
SRA 737 is all over that documentation like a scabby rash .
Its at the stage you have popped a coin into the puggy and the next press of the button is about to deliver 4 treble bars on the win line .
Jackpot
" To discuss all topics of interest to shareholders "
Ye , don't think Adam will be that keen on covering " old ground "
Nothing to do with Sareum but some very interesting news on MND treatment
https://www.bbc.com/news/health-62851186
It is nothing to do with percenteges .
It is to do with the volume and value of the purchases .
Think about it carefully .
Abers spells it out for you
Interesting
Sareum, working alongside a specialist contract research organisation (CRO), has designed a Phase 1a/b clinical trial with SDC-1801 in healthy subjects and psoriasis patients. Subject to regulatory approval from MHRA, the Phase 1a trial is planned to commence in Q4 2022 and will investigate the safety and tolerability of an oral formulation of SDC-1801 in ascending doses administered to healthy subjects. In addition, the trial will evaluate the effect of SDC-1801 on certain biomarkers of autoimmune disease that could be predictive of efficacy when tested in patients.Â
Ye no change - as per the detail in the CTA RNS
I'm surprised they did not go after someone with a bit more experience .
Joking aside , she would not have accepted the role if nothing was happening .